Unknown

Dataset Information

0

FTY-720 induces apoptosis in neuroblastoma via multiple signaling pathways.


ABSTRACT: Neuroblastoma (NB) is the most common extra-cranial pediatric solid tumor. High-risk NB is difficult to treat due to the lack of response to current therapies and aggressive disease progression. Despite novel drugs, alternative treatments and multi-modal treatments, finding an effective treatment strategy for these patients continues to be a major challenge. The current study focuses on examining the effects of FTY-720 or fingolimod, a drug that is FDA-approved for refractory multiple sclerosis, in NB. The results showed that FTY-720 regulates multiple pathways that result in various effects on calcium signaling, ion channel activation and cell survival/death pathways. FTY-720 rapidly inhibits TRPM7 channel activity, and inhibited TRPM7 kinase activity, modulates calcium signaling, induces a loss of mitochondrial membrane potential and opening of the mitochondrial permeability transition pore, and ultimately leads to cell death. Interestingly, the data also showed that low concentrations of FTY-720 sensitized drug-resistant NB cells to antineoplastic drugs. These results suggest that FTY-720 may be an attractive alternative for the treatment of NB.

SUBMITTER: Lange I 

PROVIDER: S-EPMC5746359 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

FTY-720 induces apoptosis in neuroblastoma via multiple signaling pathways.

Lange Ingo I   Espinoza-Fuenzalida Italo I   Ali Mourad Wagdy MW   Serrano Laura Espana LE   Koomoa Dana-Lynn T DT  

Oncotarget 20171106 66


Neuroblastoma (NB) is the most common extra-cranial pediatric solid tumor. High-risk NB is difficult to treat due to the lack of response to current therapies and aggressive disease progression. Despite novel drugs, alternative treatments and multi-modal treatments, finding an effective treatment strategy for these patients continues to be a major challenge. The current study focuses on examining the effects of FTY-720 or fingolimod, a drug that is FDA-approved for refractory multiple sclerosis,  ...[more]

Similar Datasets

| S-EPMC7416412 | biostudies-literature
| S-EPMC9002249 | biostudies-literature
| S-EPMC7224361 | biostudies-literature
| S-EPMC1361275 | biostudies-literature
| S-EPMC9615964 | biostudies-literature
| S-EPMC10952688 | biostudies-literature
| S-EPMC7186545 | biostudies-literature
| S-EPMC6125781 | biostudies-literature
| S-EPMC6478801 | biostudies-literature
| S-EPMC3659100 | biostudies-literature